← All trials
NCT04861948
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 25, 2021
- Primary completion
- Jun 30, 2022
- Completion date
- Oct 31, 2022
- First posted
- Apr 27, 2021
- Last posted
- Jul 20, 2021
- Enrollment
- 120
- Arms / groups
- 4 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Innovent Biologics (Suzhou) Co. Ltd.Lead sponsor
- Nanjing UniversityOverall official - principal investigator
- Tianjin Medical UniversityOverall official - principal investigator
- Xuzhou Medical UniversityOverall official - principal investigator
- Southern Medical UniversityOverall official - principal investigator
- Zhejiang UniversityOverall official - principal investigator
- Chinese Academy of Medical SciencesOverall official - principal investigator
- Central South UniversityOverall official - principal investigator
- Chinese Academy of Medical SciencesOverall official - principal investigator
- Nanjing Medical UniversityOverall official - principal investigator
- Soochow UniversityOverall official - principal investigator
- Chongqing Medical UniversityOverall official - principal investigator
- Peking UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.